US EditionNew daily pill offers hope for millions with hard to control high blood pressure
Baxdrostat, a once-daily pill blocking aldosterone production, lowered blood pressure by up to 15.7 mm Hg in a global trial, potentially aiding millions with resistant hypertension.
- A phase III trial of the drug baxdrostat showed it significantly lowered blood pressure in patients whose levels remained high despite being on other drugs.
- Baxdrostat, an experimental hypertension pill from AstraZeneca, reduced blood pressure by more than twice as much as standard treatment in a large late-stage study.
- The study's findings, published in the New England Journal of Medicine, demonstrate baxdrostat's potential in tackling one of the toughest challenges in cardiovascular care, according to AstraZeneca.
48 Articles
48 Articles
Astra pill cuts hard-to-treat blood pressure in late-stage trial
AstraZeneca Plc said its experimental hypertension pill reduced blood pressure by more than twice as much as standard treatment in a large late-stage study, bolstering its chances of competing in a crowded field.
Scientists have tested a new drug to treat high blood pressure (hypertension). The drug is called baxdrostat, and the initial results appear positive. Baxdrostat works by inhibiting the production of the hormone aldosterone. This hormone helps the kidneys regulate salt and water balance and has a significant impact on blood pressure. […] Want more science? Read the latest articles on Scientias.nl.
Doctors may soon have a new way of dealing with high blood pressure, even among people for whom drugs have not worked well in the past. Baxtrostat, an experimental medicine from AstraZeneca, showed potential in the treatment of people with uncontrolled or resistant hypertension in a recent trial. Read more Mediterranean diet and exercise prevention diabetes type 2, Harvard Study points out that the composition of popular tea can protect against …
Coverage Details
Bias Distribution
- 93% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
